EAM
SLNO

Exome Asset Management’s Soleno Therapeutics SLNO Stock Holding History

Exome Asset Management’s Portfolio SLNO Stock Details SLNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-7,100
Closed -$328K – 77
2025
Q4 		$328K Buy
+7,100
New +$389K 0.16% 60
2025
Q2 		– Sell
-11,000
Closed -$275 – 80
2025
Q1 		$275 Buy
+11,000
New +$536K ﹤0.01% 59

Other funds holding SLNO

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
KCM
Khrom Capital Management Miami Beach, Florida $1.09B AUM 14.82% 1-Year Est. Return

Exome Asset Management's SLNO Position: Q1 2026 in Review

Exome Asset Management opened a new position in Soleno Therapeutics (SLNO) in Q1 2026: 61,673 shares worth $2.06M. The stake represents 1.07% of the portfolio and ranks #40 among its holdings. This is a return to the name: Exome Asset Management previously reported a position in SLNO as recently as Q3 2025.

Exome Asset Management first reported a position in SLNO in Q4 2024 and has held it in 5 quarters since. The position peaked at $3.49M in Q2 2025. 225 funds tracked by Wall St. Rank hold SLNO as of Q1 2026.

  • Exome Asset Management held 61,673 shares of Soleno Therapeutics worth $2.06M as of Q1 2026.
  • Soleno Therapeutics was a new Exome Asset Management position in Q1 2026.
  • Soleno Therapeutics made up 1.07% of Exome Asset Management's portfolio in Q1 2026, its #40 holding.
  • Exome Asset Management first reported a position in Soleno Therapeutics in Q4 2024 and has held it in 5 quarters since.
  • Exome Asset Management's Soleno Therapeutics position peaked at $3.49M in Q2 2025.
  • 225 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q1 2026.

Based on Exome Asset Management's 13F filing for Q1 2026, filed 15 May 2026.